Nasopharyngeal Cancer Treatment Market

Nasopharyngeal Cancer Treatment Market (Treatment Type: Radiation Therapy, Chemotherapy, Immunotherapy, and Others; End-user: Hospitals, Specialty Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Nasopharyngeal Cancer Treatment Market Outlook 2031

  • The global industry was valued at US$ 574.3 Mn in 2022
  • It is projected to grow at a CAGR of 7.3% from 2023 to 2031 and reach more than US$ 1.1 Bn by 2031

Analyst Viewpoint

Increase in incidence rate and rise in smoking prevalence are driving the global nasopharyngeal cancer treatment market. Innovations in treatment technologies & therapies, improved diagnostic capabilities, and advancements in treatment options are the other major factors propelling market expansion. Furthermore, supportive reimbursement policies and investigational drugs & therapies in various stages of clinical trials are expected to bolster the global nasopharyngeal cancer treatment industry size during the forecast period.

Advancements in radiation therapy techniques, targeted therapies, immunotherapies, and minimally invasive surgical techniques offer lucrative opportunities to market players. Companies are focusing on developing therapies that have the potential to improve treatment outcomes, reduce side effects, and enhance patient quality of life.

Nasopharyngeal Cancer Treatment Market

Global Nasopharyngeal Cancer Treatment Market Overview

Nasopharyngeal cancer is a type of cancer that develops in the nasopharynx, the upper part of the throat located behind the nose. It is a relatively rare form of cancer, but its incidence rate varies across different regions.

Nasopharyngeal cancer is more commonly diagnosed in Southeast Asia, including countries such as China, Singapore, and Malaysia, where it is considered a significant health concern.

Treatment of nasopharyngeal cancer typically involves a multimodal approach, combining surgery, radiation therapy, and chemotherapy. The specific treatment plan depends on factors such as the stage of cancer, the extent of the tumor, and the patient's overall health condition.

The past few years have witnessed advancements in treatment approaches for nasopharyngeal cancer. These include usage of intensity-modulated radiation therapy (IMRT) and proton therapy, which allow for more precise targeting of the tumor while minimizing damage to surrounding healthy tissues.

Targeted therapies and immunotherapies are also being explored as potential treatment options, aiming to specifically target cancer cells and boost the body's immune response against the tumor.

Overall, management of nasopharyngeal cancer requires a multidisciplinary approach involving oncologists, radiation oncologists, surgeons, and other healthcare professionals. Ongoing research and advancements in treatment options continue to improve outcomes and enhance the quality of life for individuals affected by nasopharyngeal cancer.

High Incidence Rate of Nasopharyngeal Cancer Specifically in Countries in Asia

Nasopharyngeal cancer (NPC) is considered a rare malignancy in most parts of the world, with age-standardized incidence rates generally below 1 per 100,000 person-years. However, certain populations, such as the Cantonese population of southern China and indigenous populations in Southeast Asia, have substantially higher incidence rates.

Globally, in 2020, an estimated 133,354 new cases of nasopharyngeal cancer were diagnosed, with 85% of these cases occurring in Asia. It ranked as the 23rd most common incident cancer worldwide and the 21st most common cause of cancer-related deaths, with approximately 80,008 deaths attributed to NPC (APAC=68,434 Deaths). In Southeast Asia, nasopharyngeal cancer ranked 9th among incident cancers and 8th among cancer-related deaths.

The North-Eastern (NE) region of India faces the highest incidence of nasopharyngeal cancer in the country, accompanied by a greater prevalence of risk factors and insufficient access to cancer treatment facilities.

Increase in prevalence of these conditions is likely to fuel the demand for effective therapeutics for nasopharyngeal carcinoma to manage and treat these conditions. This, in turn, is estimated to propel the nasopharyngeal cancer treatment market value in the near future.

Increase in Smoking Prevalence Propelling Market Development

Smoking is one of the major risk factors for nasopharyngeal cancer, and the prevalence of smoking among Asian men has been increasing, which is likely to drive the nasopharyngeal cancer patient population, and eventually the nasopharyngeal cancer treatment market growth.

Several factors contribute to the increasing prevalence of smoking among Asian men. One of the major reasons is the aggressive marketing strategies of tobacco companies in countries in the region, where regulations on tobacco advertising and promotion are often weak.

Cultural factors such as the perception of smoking as a symbol of masculinity and social status and the lack of awareness about the health risks associated with smoking also contribute to the high smoking rates among men in the region.

China, the most populous country in the world, has the largest number of smokers globally. Similarly, in Indonesia, the prevalence of smoking among men is also exceptionally high. According to the 2018 RISKESDAS survey, a national health survey in Indonesia, 47% of men and 1% of women aged 10 years or older smoke kreteks, white cigarettes, and/or roll-your-own cigarettes daily.

Carcinogens present in tobacco smoke can damage the DNA in the nasopharyngeal cells, leading to the development of cancerous growth. The social acceptance and cultural norms associated with smoking in several countries in Asia contribute to the high smoking rates among men, thus elevating the NPC risk.

This highlights the importance of spreading awareness about the health risks associated with smoking and officially launching effective nasopharyngeal cancer treatments, particularly in high-risk populations. Additionally, increase in investment in research & development in could lead to better outcomes for patients and improve their quality of life. This could also offer companies significant nasopharyngeal cancer treatment business opportunities in the next few years.

Surge in Demand for Chemotherapy for Treatment of Nasopharyngeal Cancer

In terms of treatment type, the chemotherapy segment accounted for the largest global nasopharyngeal cancer treatment market share in 2022. High incidence rate of NPC in China, Japan, and countries in southeast Asia is projected to drive the segment during the forecast period.

As per data published by WHO, in endemic areas such as southeast Asia and southern China (e.g., Hong Kong Special Administrative Region), the annual age-standardized incidence rates in men and women are as high as 20–30 and 8–15 cases per 100,000 people, respectively.

Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating the Epstein‐Barr Virus. Notable burden of tobacco-use in China is likely to drive the adoption of chemotherapy during the forecast period.

For instance, 30% of the world’s smokers live in China. Over 300 million adults in the country smoke tobacco. Smoking rate in China is one of the highest in the world, with 52.9% of adult males and 2.4% of adult women being current smokers.

Availability of Specialized Infrastructure and Expertise in Oncology in Hospitals

Based on end-user, the hospitals segment is projected to dominate the global nasopharyngeal cancer treatment market demand during the forecast period. This is ascribed to specialized infrastructure and expertise in oncology available in hospitals.

These healthcare facilities have state-of-the-art equipment and experienced healthcare professionals who specialize in the management of cancer. This expertise allows for accurate diagnosis and appropriate patient selection, ensuring optimal outcomes.

However, according to nasopharyngeal cancer treatment market forecast, major technological innovations are likely to propel the specialty clinics segment. Over the years, there have been significant advancements in the diagnosis and treatment of cancer. These include improvements in imaging technologies, radiation therapy techniques, targeted therapies, and immunotherapy.

Specialty clinics that stay up-to-date with the latest research and treatment options can offer patients access to innovative therapies, leading to better outcomes and attracting more patients seeking specialized care

Rapid growth of the specialty clinics segment is ascribed to availability of advanced medical facilities, expertise of healthcare professionals, access to specialized equipment, and the overall healthcare infrastructure in the region.

Regional Outlook

According to nasopharyngeal cancer treatment market trends, Asia Pacific dominated the global industry in 2023. Universities operating in countries in Asia play a crucial role in driving research and innovation in the healthcare industry, including in the field of nasopharyngeal cancer treatment.

Development of targeted therapies is one area where universities are making significant strides in the nasopharyngeal carcinoma therapy market. These therapies aim to specifically target cancer cells while sparing healthy cells and reducing the side effects associated with traditional cancer treatments.

For instance, in May 2020, a research team led by Hong Kong Baptist University (HKBU), developed a new drug with the potential to become a next-generation treatment for cancers linked to the Epstein-Barr virus (EBV).

Usage of immunotherapy in nasopharyngeal cancer treatment is another area of innovation. Immunotherapy works by boosting the body's immune system to recognize and attack cancer cells.

Researchers at the Sun Yat-sen University Cancer Center in China have developed a novel immunotherapy approach using a personalized cancer vaccine that is tailored to each patient's specific cancer cells. This approach has shown promising results in early clinical trials, and it could offer a new treatment option for patients with advanced nasopharyngeal cancer.

In February 2023, scientists from Sun Yat-sen University conducted a phase III clinical trial, the results of which show that medial retropharyngeal nodal region sparing radiotherapy, compared with standard radiotherapy in patients with nasopharyngeal carcinoma, provides non-inferior local relapse-free survival. Thus, universities play a vital role in driving research and innovation in the market in Asia Pacific.

However, as per nasopharyngeal cancer treatment market analysis, North America is the second largest market for nasopharyngeal cancer treatment, with the U.S being the largest contributor to market revenue. Rise in prevalence of NPC across the Chinese-American citizens is one of the key drivers of the market in the region.

Analysis of Key Players

The global nasopharyngeal cancer treatment market report provides profiles of prominent players. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand presence and gain market share.

Biocon Limited, BeiGene Ltd., Shanghai Junshi Biosciences Co., Ltd., Innogene Kalbiotech, Center of Molecular Immunology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc., and Biosyngen Pte. Ltd. are the prominent players in the market.

Key Developments in Global Nasopharyngeal Cancer Treatment Industry

  • In June, 2023 Biosyngen Pte. Ltd. (Biosyngen) announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) granted its application, for immune cell therapy BRG01 for the treatment of nasopharyngeal cancer, the status of Orphan Drug Designation (ODD)
  • In October 2022, Indonesia’s FDA (BPOM) approved new indication “Locally advanced non-nasopharyngeal Squamous Cell Carcinoma of Head and Neck (SCCHN) (Stage III or IV A/B) in combination with concurrent chemoradiotherapy" for Theracim (Nimotuzumab)
  • In July 2022, Shanghai Junshi Biosciences Co., Ltd, a prominent innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (EC) for the treatment of nasopharyngeal carcinoma (“NPC”), following the favorable opinion of the European Medicines Agency (EMA).
  • In June 2022, BeiGene announced that the China National Medical Products Administration (NMPA) approved its anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC).

The nasopharyngeal cancer treatment market research report profiles the top players based on various parameters including company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Global Nasopharyngeal Cancer Treatment Market Snapshot

Attribute Detail
Size in 2022 US$ 574.3 Mn
Forecast (Value) in 2031 More than US$ 1.1 Bn
Growth Rate (CAGR) 7.3%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Mn/Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment Type
    • Radiation Therapy
    • Chemotherapy
    • Immunotherapy
    • Others (surgery, targeted therapy, etc.)
  • End-user
    • Hospitals
    • Specialty Clinics
    • Others (research institutes, etc.)
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Biocon Limited
  • BeiGene Ltd.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Innogene Kalbiotech
  • Center of Molecular Immunology
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Biosyngen Pte. Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global nasopharyngeal cancer treatment market in 2022?

It was valued at US$ 574.3 Mn in 2022

How big will the nasopharyngeal cancer treatment business be in 2031?

It is projected to reach more than US$ 1.1 Bn by 2031

What will the CAGR of nasopharyngeal cancer treatment sector be during the forecast period?

It is anticipated to grow at a CAGR of 7.3% from 2023 to 2031

Which are the prominent trends driving demand for nasopharyngeal cancer treatment?

Increase in incidence rate of nasopharyngeal cancer and surge in smoking prevalence

Which region will account for major share of nasopharyngeal cancer treatment industry during the forecast period?

Asia Pacific is projected to account for significant share during the forecast period

Who are the prominent players in nasopharyngeal cancer treatment domain?

Biocon Limited, BeiGene Ltd., Shanghai Junshi Biosciences Co., Ltd., Innogene Kalbiotech, Center of Molecular Immunology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc., and Biosyngen Pte. Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nasopharyngeal Cancer Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, 2023–2031

5. Key Insights

    5.1. Disease Epidemiology

    5.2. Pipeline Analysis

    5.3. List of Drugs Approved for Nasopharyngeal Cancer

    5.4. Key Industry Events (product launches/mergers, acquisitions & partnerships)

    5.5. COVID-19 Pandemic Impact on Industry

6. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        6.3.1. Radiation therapy

        6.3.2. Chemotherapy

        6.3.3. Immunotherapy

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by End-user, 2023–2031

        7.3.1. Hospitals

        7.3.2. Specialty Clinics

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Nasopharyngeal Cancer Treatment Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Nasopharyngeal Cancer Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        9.2.1. Radiation therapy

        9.2.2. Chemotherapy

        9.2.3. Immunotherapy

        9.2.4. Others

    9.3. Market Value Forecast, by End-user, 2023–2031

        9.3.1. Hospitals

        9.3.2. Specialty Clinics

        9.3.3. Others

    9.4. Market Value Forecast, by Country, 2023–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Treatment Type

        9.5.2. By End-user

        9.5.3. By Country

10. Europe Nasopharyngeal Cancer Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        10.2.1. Radiation therapy

        10.2.2. Chemotherapy

        10.2.3. Immunotherapy

        10.2.4. Others

    10.3. Market Value Forecast, by End-user, 2023–2031

        10.3.1. Hospitals

        10.3.2. Specialty Clinics

        10.3.3. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Treatment Type

        10.5.2. By End-user

        10.5.3. By Country/Sub-region

11. Asia Pacific Nasopharyngeal Cancer Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        11.2.1. Radiation therapy

        11.2.2. Chemotherapy

        11.2.3. Immunotherapy

        11.2.4. Others

    11.3. Market Value Forecast, by End-user, 2023–2031

        11.3.1. Hospitals

        11.3.2. Specialty Clinics

        11.3.3. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Treatment Type

        11.5.2. By End-user

        11.5.3. By Country/Sub-region

12. Latin America Nasopharyngeal Cancer Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        12.2.1. Radiation therapy

        12.2.2. Chemotherapy

        12.2.3. Immunotherapy

        12.2.4. Others

    12.3. Market Value Forecast, by End-user, 2023–2031

        12.3.1. Hospitals

        12.3.2. Specialty Clinics

        12.3.3. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Treatment Type

        12.5.2. By End-user

        12.5.3. By Country/Sub-region

13. Middle East & Africa Nasopharyngeal Cancer Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value & Volume Forecast, by Treatment Type, 2023–2031

        13.2.1. Radiation therapy

        13.2.2. Chemotherapy

        13.2.3. Immunotherapy

        13.2.4. Others

    13.3. Market Value Forecast, by End-user, 2023–2031

        13.3.1. Hospitals

        13.3.2. Specialty Clinics

        13.3.3. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of MEA

    13.5. Market Attractiveness Analysis

        13.5.1. By Treatment Type

        13.5.2. By End-user

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company (2022)

    14.3. Company Profiles

        14.3.1. Biocon Limited

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. Financial Overview

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. BeiGene Ltd.

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. Financial Overview

            14.3.2.4. SWOT Analysis

            14.3.2.5. Strategic Overview

        14.3.3. Shanghai Junshi Biosciences Co., Ltd.

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. Financial Overview

            14.3.3.4. SWOT Analysis

            14.3.3.5. Strategic Overview

        14.3.4. Innogene Kalbiotech

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. Financial Overview

            14.3.4.4. SWOT Analysis

            14.3.4.5. Strategic Overview

        14.3.5. Center of Molecular Immunology

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. Financial Overview

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. Financial Overview

            14.3.6.4. SWOT Analysis

            14.3.6.5. Strategic Overview

        14.3.7. Bristol-Myers Squibb Company

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. Financial Overview

            14.3.7.4. SWOT Analysis

            14.3.7.5. Strategic Overview

        14.3.8. Merck & Co., Inc.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. Financial Overview

            14.3.8.4. SWOT Analysis

            14.3.8.5. Strategic Overview

        14.3.9. Biosyngen Pte. Ltd.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. Financial Overview

            14.3.9.4. SWOT Analysis

            14.3.9.5. Strategic Overview

List of Tables

Table 01: Global Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 02: Global Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 03: Global Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Region, 2023–2031

Table 04: North America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 05: North America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 06: North America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Country, 2023–2031

Table 07: Europe Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 08: Europe Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 09: Europe Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 10: Asia Pacific Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 11: Asia Pacific Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 12: Asia Pacific Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 13: Latin America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 14: Latin America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 15: Latin America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 16: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 17: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2023–2031

Table 18: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

List of Figures

Figure 01: Global Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 03: Global Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 04: Global Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 05: Global Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 06: Global Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Region, 2022 and 2031

Figure 07: Global Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 08: North America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2023–2031

Figure 09: North America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 10: North America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 11: North America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 12: North America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 13: North America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Country, 2022 and 2031

Figure 14: North America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 15: Europe Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2023–2031

Figure 16: Europe Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 17: Europe Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 18: Europe Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 19: Europe Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 20: Europe Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: Europe Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 22: Asia Pacific Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2023–2031

Figure 23: Asia Pacific Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 24: Asia Pacific Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 25: Asia Pacific Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 26: Asia Pacific Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 27: Asia Pacific Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 28: Asia Pacific Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 29: Latin America Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2023–2031

Figure 30: Latin America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 31: Latin America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 32: Latin America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 33: Latin America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 34: Latin America Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 35: Latin America Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value (US$ Mn) Forecast, 2023–2031

Figure 37: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 38: Middle East & Africa Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 39: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031

Figure 40: Middle East & Africa Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by End-user, 2022–2031

Figure 41: Middle East & Africa Nasopharyngeal Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 42: Middle East & Africa Nasopharyngeal Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 43: Global Nasopharyngeal Cancer Treatment Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved